Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The FDA issued multiple breakthrough approvals for oncology drugs in November 2025, marking a transformative...
SAN FRANCISCO and SUZHOU, China , Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
Safusidenib demonstrated durable responses, with an ORR of 44% and 88% of patients were progression-free at 24 months Findings supported recent favorable interactions...
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive...
Successfully started 204 patients on IBTROZI ™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI’s unprecedented durability...
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive...
No targeted treatments are currently FDA approved for high-grade IDH1 -mutant gliomas After a favorable meeting with FDA, protocol amendment will make G203...
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday,...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cullinan Management (CGEM – Research Report), Nuvation Bio (NUVB – Research Report) and QT Imaging Holdings...
In a report released on October 8, Leonid Timashev from RBC Capital maintained a Buy rating on Nuvation Bio. The company’s shares closed yesterday at $3.75.Elevate Your Investing Strategy: Take advantage...